zum Inhalt
Header Image

Personalisierte Medizin: Vision und Wirklichkeit

-
Erwin-Schrödinger-Saal
Plenary / Panel
in deutscher Sprache

Vortragende

Professorin, Klinische Abteilung für Hämatologie und Hämostaseologie, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien Abstract
Das Ziel der personalisierten Medizin ist es, die richtige Diagnose und Therapie zum richtigen Zeitpunkt für den richtigen Patienten (die richtige Person) anzuwenden. Dieses Ziel ist nicht neu, sondern eigentlich die Grundlage jedes medizinischen Handelns, jedoch hat sich in den letzten Jahren das diagnostische und therapeutische Spektrum wesentlich erweitert und umfasst neben der individuellen und familiären Vorgeschichte und der klinischen Präsentation genetische Information und biochemische Marker. Die meisten der derzeit gültigen medizinischen Leitlinien basieren auf Studien, in die Patienten mit ähnlicher medizinischer Präsentation eingebracht wurden. Oben genannte Aspekte genetischer Profile und biochemischer Marker wurden in diesen Studien meist noch nicht berücksichtigt. In der Thrombose- und Blutgerinnungsforschung gibt es bereits Erkenntnisse über die Anwendung solcher Marker für die individualisierte Therapie und Prophylaxe von Venenthrombosen. So gelingt es bei Krebspatienten durch eine Kombination von klinischen Aspekten und Biomarkern, das Erstauftreten von Venenthrombosen bzw Lungeninfarkten, einer häufigen aber verhinderbaren Komplikation bei Krebserkrankungen, mit einer Wahrscheinlichket von 99% auszuschließen bzw mit 43% vorherzusagen. Eine vorbeugende Behandlung kann damit wesentlich gezielter bei einer bestimmten Gruppe von Patienten eingesetzt werden. Wichtig erscheint in diesem Zusammenhang auch die Möglichkeit der besseren individuellen Beratung und damit der größeren Entscheidungsfreiheit aber auch Eigenverantwortung jedes einzelnen Betroffenen.

The goal of personalized medicine is to provide the right diagnosis and treatment to the right patient at the right time at the right cost.
Global Head of Development, pRED - Pharma Research & Exploratory Development, F. Hoffmann-La Roche AG, Basel Abstract
Personalised Healthcare (PHC): Vision and Reality

Vision: PHC represents a major shift in the treatment paradigm.
Conventional medicines have traditionally been prescribed on a  trial-and-error basis that is effective only about half of the time. Using personalised approaches will allow us to identify and target patients who are most likely to respond to specific treatment. This should improve clinical outcomes and avoid patient exposure to potential side effects, which will deliver sustainable value for the entire healthcare community.

Reality: Progress in basic science has not yet been fully translated into therapeutic benefit for patients.
Translating the molecular understanding of disease into the clinical setting (i.e.  Bench to Bedside ) is essential for PHC.

PHC is core to the Roche strategy.
Combining Pharma and Diagnostics expertise can enable unrestricted collaboration on products across the entire healthcare spectrum  from early detection and diagnosis to treatment and monitoring of patients and therapy. Roche has a track record of developing pioneering solutions in PHC (e.g. Herceptin/HER2 Test,HIV, HCV) and continues to build a rich PHC portfolio.

The progress in technology and knowledge offers great opportunities for improved and more predictive treatments and has the potential to change the practice of medicine.
Professor and Director, Human Genetics Division, Innsbruck Medical University, Innsbruck
Vice President, European Forum Alpbach; Professor and Chair, Department of Ophthalmology, Medical University of Vienna Chair

Dr. Ingrid PABINGER-FASCHING

Professorin, Klinische Abteilung für Hämatologie und Hämostaseologie, Universitätsklinik für Innere Medizin I, Medizinische Universität Wien

 Ingrid Pabinger-Fasching started her scientific and clinical career in 1982 at the Medical University Clinic of Vienna, with particular scientific focus on hereditary and acquired thrombosis risk factors (molecular and biochemical basis, aspects of diagnosis, clinical features and therapy), aspects of haemophilia treatment and acquired hemorrhagic diathesis, fundamentals and clinical relevance of coagulation abnormalities in patients with oncologic and haemato-oncologic diseases, clinical and immunologic characteristics of patients with immune-thrombocytopenia, and specific haemostaseologic problems in critically-ill patients. In 1982 and 1985 she stayed in the laboratory of Prof.Dr.R.M. Bertina in Leiden, the Netherlands for periods of several weeks for scientic research.
 Since 1990 she leads a scientific working group. Since 2004 she holds the position of Professor of Hemostaseology at the Medical University of Vienna, and since 2008 she is vice-director of the Division of Hematology and Hemostaseology in the Department of Medicine I.

Dr. Andreas WALLNÖFER

Global Head of Development, pRED - Pharma Research & Exploratory Development, F. Hoffmann-La Roche AG, Basel

 Ph.D. at the University of Basel, Post-doc fellowship in Clinical Pharmacology at the University Hospital Leiden, Netherlands; Business training at IMD Lausanne
1987 Basic Research, Cardiovascular Discovery Research, Sandoz
1991 Clinical Investigator, Centre for Human Drug Research, Leiden
1992 Clinical Pharmacologist, Roche
1996 Clinical Science and Clinical Team Leader, Cardiovascular Clinical Research, Roche
1999 Project Leader, R&D Project Management, Roche
2002 Global Head, Early Development Project Leaders and Project Management, Roche
2007 Global Head, Clinical Research & Exploratory Development, Roche
2010 Global Head of Development, Roche Pharma Research & Exploratory Development (pRED)

DDr. med. Johannes ZSCHOCKE

Professor and Director, Human Genetics Division, Innsbruck Medical University, Innsbruck

1984-1991 Medical Studies, Freiburg (Germany) & Belfast (Northern Ireland);
1991-1995 Junior doctor and Research Fellow, Queen's University Belfast;
1995-1999 Univ. Children's Hospital, Marburg, Germany;
2000-2008 Institute of Human Genetics, Heidelberg University, Germany;
since 2008 Professor of Human Genetics, Innsbruck

Dr. Ursula SCHMIDT-ERFURTH

Vice President, European Forum Alpbach; Professor and Chair, Department of Ophthalmology, Medical University of Vienna

1979-1986 Medical School, Ludwig-Maximilians-University, Munich
1986 Doctoral thesis, University Eye Hospital, Munich
1986 Internal rotation in Ophthalmic Pathology Howe Laboratory, Harvard Medical School, Mass. Eye and Ear Infirmary, Boston, MA
1986-1987 Research Fellow, Institute of Immunology, Ludwig-Maximilians-University, Munich
1987-1990 Resident in Ophthalmology, University Eye Hospital, Munich
1990-1992 Research Fellow in Photomedicine, Wellman Laboratories, Mass. General Hospital, Harvard Medical School, Boston, MA
1991-1992 Research Fellow in Ophthalmology, Retina-Department, Massachusetts Ear Infirmary, Harvard Medical School, Boston, MA
1992-1993 Clinical Fellow in Medical Retina, University Eye Hospital, Medical University of Lübeck
1992-2004 Research Associate, Medical Laser Center, University of Lübeck, Germany
1993-1995 Instructor in Ophthalmology, University Eye Hospital Lübeck
1996-1999 Assistant Professor in Ophthalmology, University Eye Hospital Lübeck
2000-2004 Professor in Ophthalmology
since 2004 Appointment at the University of Vienna, Professor and Chair of Ophthalmology
2008 Visiting Professorship: Mc Gill University / Montreal / Canada
since 2009 Lecturer, ESASO - European School for Advanced Studies in Ophthalmology, Lugano
since 2009 Lecturer, PhD-Program at CeMM, Center for Molecular Medicine, Academy of Sciences, Vienna
since 2010 Elected member of the Senate, MUW - Medical University of Vienna

Gesundheitsgespräche

Timetable einblenden